LCIV

25.5291.79%

Sanofi's Sarclisa Moves Toward Broader First-Line Access In Canada

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Add Sanofi's Sarclisa Moves Toward Broader First-Line Access In Canada as your preferred news source on Google

Add Now

Sanofi SA (SNY) signed a Letter of Intent with Canada's pan-Canadian Pharmaceutical Alliance (pCPA) following successful negotiations to expand public access to Sarclisa (isatuximab) for adults with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation.

The agreement covers Sarclisa combined with bortezomib, lenalidomide and dexamethasone (VRd) as a first-line treatment. Public coverage will depend on final funding agreements with individual provinces and territories.

In the Phase 3 IMROZ study, 63% of patients receiving Sarclisa plus VRd remained progression-free after approximately five years, compared with 45% receiving VRd alone.

Currently, SNY is trading at $48.79, up 0.84%

For comments and feedback contact: editorial@rttnews.com

Business News

Source: rttnews The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.